A method of treating or preventing overgrowth by pathogenic bacteria in a subject deficient in butyrate and/or butyrate-producing bacteria in their gut microbiota by administering a therapeutically effective amount of a butyrate-producing bacteria to the subject is described. A prebiotic can be included with the butyrate-producing bacteria. Overgrowth by pathogenic bacteria is commonly caused by antibiotic administration.

A method of treating or preventing overgrowth by pathogenic bacteria in a subject deficient in butyrate and/or butyrate-producing bacteria in their gut microbiota by administering a therapeutically effective amount of a butyrate-producing bacteria to the subject is described. A prebiotic can be included with the butyrate-producing bacteria. Overgrowth by pathogenic bacteria is commonly caused by antibiotic administration.

The pharmaceutical composition constituted by carboxymethylated starch and citric acid, a citrate, or mixtures thereof, prevents adhesion of injured mesothelial surfaces and the formation of adhesion bands between the mesothelia at the highest level. The composition in gel form acts as a matrix in which connective tissue healing of tissue defects is promoted.

The pharmaceutical composition constituted by carboxymethylated starch and citric acid, a citrate, or mixtures thereof, prevents adhesion of injured mesothelial surfaces and the formation of adhesion bands between the mesothelia at the highest level. The composition in gel form acts as a matrix in which connective tissue healing of tissue defects is promoted.

Starch propionate for humans is provided for weight loss and prevention of overweight and obesity. Starch propionate functions as a platform for delivery of propionic acid in the colon. It passes un-degraded to the colon, where propionic acid is released. Propionic acid in the colon stimulates the intestinal membrane to release appetite suppressing hormones GLP-1,(GLP-2) and PPY that reduces calorie intake and inhibits the production of fat in the liver and fat-tissue. Increased propionic acid in the blood inhibits fat production in the liver and fat-tissue. It also promotes the development of the gastrointestinal tract. Starch propionate can be used to reduce the appetite and calorie intake in humans.

The present disclosure relates to highly resistant starch compositions, methods for preparing such highly resistant starch compositions, and methods of using such highly resistant starch compositions to treat or prevent a disease or condition associated with dysregulation and/or dysfunction of the intestinal microbiome.

The present disclosure relates to highly resistant starch compositions, methods for preparing such highly resistant starch compositions, and methods of using such highly resistant starch compositions to treat or prevent a disease or condition associated with dysregulation and/or dysfunction of the intestinal microbiome.

A composition containing hydroxytyrosol and punicalagin for use in the treatment of dyslipidemia in a subject in need thereof. The hydroxytyrosol may be obtained from olives. The punicalagin may be obtained from pomegranates. The concentration of hydroxytyrosol in the composition may be between 0.5% and 5% (w/w) of the total composition. The concentration of punicalagins in the composition may be between 10% and 25% (w/w) of the total composition. The composition may further contain maltodextrin, and the concentration of maltodextrin may be between 40% and 85% (w/w) of the total composition.

An ocular medical injector is provided for drug delivery. A method includes inserting a puncture member of the medical injector into the eye until the puncture member reaches the SCS. The puncture member defines a lumen therethrough. With the puncture member disposed within the SCS, a flexible cannula is advanced distally through the lumen of the puncture member, beyond the distal end portion of the puncture member and along the SCS towards a posterior region of the eye. The flexible cannula has an atraumatic distal tip and defines a lumen therethrough. With the distal tip of the flexible cannula disposed within the SCS beyond a distal end portion of the puncture member, a therapeutic substance is administered to the SCS.

The present invention concerns an edible ingredient providing a short chain fatty acid ratio in the gut such that acetate is n a ratio ranging from 70 to 80, propionate is in a ratio ranging from 2 to 8, butyrate is in a ratio ranging from 20 to 25 and wherein the sum of individual ratios for acetate, propionate and butyrate equals 100 to food compositions comprising such edible ingredient for use in the attenuation of stress response and/or prevention of chronic stress and of conditions thereby associated.